Inclusion Criteria
Patients must have:
- HIV infection.
- CD4 count >= 500 cells/mm3.
- No evidence of AIDS.
- No antiretroviral therapy within 30 days prior to study entry.
NOTE:
- Presence of lymphadenopathy in two or more extrainguinal sites, at least 1 cm in diameter for 3 or more months, is permitted.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Clinically significant abnormalities on routine hematology (other than CD4 count and Western blot), serum chemistry, and urinalysis.
- Abnormal EKG.
- Positive stool guaiac.
- Abnormal medical history or physical exam including temperature, heart rate, and blood pressure.
- Clinically significant organ abnormality or disease.
- Positive urine drug screen for illicit drugs.
- Inability to comply with study procedures.
Concurrent Medication:
Excluded:
- Routine treatment with nonprescription medications.
- Treatment with other medications except with approval of the investigator.
Patients with the following prior conditions are excluded:
- Prior participation in this trial.
- Serious physical or mental illness within 1 year prior to study entry that would confound interpretation of data.
Prior Medication:
Excluded:
- Antiretroviral therapy within 30 days prior to study entry.
- Known medications that alter renal, hepatic, or hematologic/immunologic function (such as barbiturates, phenothiazines, cimetidine, and immunomodulators) within 14 days prior to study entry.
- Routine treatment with nonprescription medications within 3 days prior to study entry.
History of alcohol or drug abuse within the past year.
Purpose
